Form 4: Teva Pharmaceutical Director Varda Shalev Reports Share Transactions
SEC Filing
Director Varda Shalev reports the acquisition and disposal of Teva Pharmaceutical Industries Ltd. ordinary shares related to vested restricted share units.
Summary
- On September 4, 2024, Varda Shalev, a director of Teva Pharmaceutical Industries Ltd., filed a Form 4 with the SEC.
- The report details transactions on September 2, 2024, involving ordinary shares and restricted share units.
- Shalev acquired 12,872 ordinary shares through the vesting of restricted share units.
- Simultaneously, Shalev disposed of 12,872 ordinary shares.
- The restricted share units, granted on September 2, 2023, vested on September 2, 2024, each representing a contingent right to receive one ordinary share or its cash value.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock transactions by a company director, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and does not necessarily indicate a significant event for Teva Pharmaceutical Industries Ltd.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it primarily concerns the director's compensation.
Key Dates
| Date | Description |
|---|---|
| 09/02/2023 | Restricted share units were granted. |
| 09/02/2024 | Restricted share units vested, resulting in the acquisition and disposal of ordinary shares. |
| 09/04/2024 | Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.